Based on the Modalis Therapeutics Corp stock forecast from 0 analysts, the average analyst target price for Modalis Therapeutics Corp is not available over the next 12 months. Modalis Therapeutics Corp’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Modalis Therapeutics Corp is Very Bearish, which is based on 0 positive signals and 9 negative signals. At the last closing, Modalis Therapeutics Corp’s stock price was JPY 135.00. Modalis Therapeutics Corp’s stock price has changed by -4.26% over the past week, +2.27% over the past month and +9.76% over the last year.
No recent analyst target price found for Modalis Therapeutics Corp
No recent average analyst rating found for Modalis Therapeutics Corp
Company Overview Modalis Therapeutics Corp
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd. to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was founded in 2016 and is headquartered in Tokyo, Japan. Read Less
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through...Read More
Frequently Asked Questions About Modalis Therapeutics Corp (4883:TSE) Stock
Stock Target Advisor's fundamental analysis for Modalis Therapeutics Corp's stock is Very Bearish.
Unfortunately we do not have enough data on 4883:TSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4883:TSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 4883:TSE's stock to indicate if its overvalued.
The last closing price of 4883:TSE's stock was JPY 135.00.
The most recent market capitalization for 4883:TSE is JPY 6.69B.
Unfortunately we do not have enough analyst data on 4883:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Modalis Therapeutics Corp's stock.
As per our most recent records Modalis Therapeutics Corp has 37 Employees.
Modalis Therapeutics Corp's registered address is Y?s Building, Tokyo, Japan, 103-0026.
You can get more information about it from Modalis Therapeutics Corp's website at https://modalistx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Modalis Therapeutics Corp (4883:TSE) Stock
Stock Target Advisor's fundamental analysis for Modalis Therapeutics Corp's stock is Very Bearish.
Unfortunately we do not have enough data on 4883:TSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4883:TSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 4883:TSE's stock to indicate if its overvalued.
The last closing price of 4883:TSE's stock was JPY 135.00.
The most recent market capitalization for 4883:TSE is JPY 6.69B.
Unfortunately we do not have enough analyst data on 4883:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Modalis Therapeutics Corp's stock.
As per our most recent records Modalis Therapeutics Corp has 37 Employees.
Modalis Therapeutics Corp's registered address is Y?s Building, Tokyo, Japan, 103-0026.
You can get more information about it from Modalis Therapeutics Corp's website at https://modalistx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4883:TSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
